GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (LTS:0MGB) » Definitions » Cyclically Adjusted PS Ratio

Genmab A/S (LTS:0MGB) Cyclically Adjusted PS Ratio : 17.32 (As of Jun. 06, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Genmab A/S Cyclically Adjusted PS Ratio?

As of today (2024-06-06), Genmab A/S's current share price is kr1949.00. Genmab A/S's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was kr112.50. Genmab A/S's Cyclically Adjusted PS Ratio for today is 17.32.

The historical rank and industry rank for Genmab A/S's Cyclically Adjusted PS Ratio or its related term are showing as below:

LTS:0MGB' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 17.08   Med: 50.79   Max: 72.33
Current: 17.18

During the past years, Genmab A/S's highest Cyclically Adjusted PS Ratio was 72.33. The lowest was 17.08. And the median was 50.79.

LTS:0MGB's Cyclically Adjusted PS Ratio is ranked worse than
80.16% of 504 companies
in the Biotechnology industry
Industry Median: 5.525 vs LTS:0MGB: 17.18

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Genmab A/S's adjusted revenue per share data for the three months ended in Mar. 2024 was kr63.099. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is kr112.50 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Genmab A/S Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Genmab A/S's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab A/S Cyclically Adjusted PS Ratio Chart

Genmab A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 52.44 58.20 47.27 36.10 20.44

Genmab A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.97 28.11 25.22 20.44 18.48

Competitive Comparison of Genmab A/S's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Genmab A/S's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab A/S's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab A/S's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Genmab A/S's Cyclically Adjusted PS Ratio falls into.



Genmab A/S Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Genmab A/S's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1949.00/112.5
=17.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab A/S's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Genmab A/S's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=63.099/118.4000*118.4000
=63.099

Current CPI (Mar. 2024) = 118.4000.

Genmab A/S Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 2.040 99.700 2.423
201409 4.720 99.700 5.605
201412 3.734 99.400 4.448
201503 1.789 100.200 2.114
201506 2.847 100.300 3.361
201509 4.555 100.200 5.382
201512 9.668 99.800 11.470
201603 2.805 100.200 3.314
201606 5.721 100.600 6.733
201609 5.905 100.200 6.978
201612 14.986 100.300 17.690
201703 4.050 101.200 4.738
201706 12.458 101.200 14.575
201709 5.124 101.800 5.960
201712 16.348 101.300 19.108
201803 10.975 101.700 12.777
201806 8.236 102.300 9.532
201809 9.655 102.400 11.164
201812 19.901 102.100 23.078
201903 9.604 102.900 11.051
201906 12.293 102.900 14.145
201909 16.036 102.900 18.452
201912 45.008 102.900 51.788
202003 13.562 103.300 15.544
202006 82.862 103.200 95.066
202009 26.153 103.500 29.918
202012 30.932 103.400 35.419
202103 23.960 104.300 27.199
202106 29.902 105.000 33.718
202109 34.961 105.800 39.125
202112 38.614 106.600 42.888
202203 32.127 109.900 34.612
202206 47.924 113.600 49.949
202209 62.001 116.400 63.066
202212 77.751 115.900 79.428
202303 43.050 117.300 43.454
202306 63.759 116.400 64.855
202309 72.017 117.400 72.630
202312 70.839 116.700 71.871
202403 63.099 118.400 63.099

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Genmab A/S  (LTS:0MGB) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Genmab A/S Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Genmab A/S's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab A/S (LTS:0MGB) Business Description

Industry
Address
Kalvebod Brygge 43, Copenhagen, DNK, 1560
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab A/S (LTS:0MGB) Headlines

No Headlines